BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22388726)

  • 1. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia.
    Inthal A; Zeitlhofer P; Zeginigg M; Morak M; Grausenburger R; Fronkova E; Fahrner B; Mann G; Haas OA; Panzer-Grümayer R
    Leukemia; 2012 Aug; 26(8):1797-803. PubMed ID: 22388726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.
    Malinowska-Ozdowy K; Frech C; Schönegger A; Eckert C; Cazzaniga G; Stanulla M; zur Stadt U; Mecklenbräuker A; Schuster M; Kneidinger D; von Stackelberg A; Locatelli F; Schrappe M; Horstmann MA; Attarbaschi A; Bock C; Mann G; Haas OA; Panzer-Grümayer R
    Leukemia; 2015 Aug; 29(8):1656-67. PubMed ID: 25917266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CREBBP mutations in relapsed acute lymphoblastic leukaemia.
    Mullighan CG; Zhang J; Kasper LH; Lerach S; Payne-Turner D; Phillips LA; Heatley SL; Holmfeldt L; Collins-Underwood JR; Ma J; Buetow KH; Pui CH; Baker SD; Brindle PK; Downing JR
    Nature; 2011 Mar; 471(7337):235-9. PubMed ID: 21390130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MSH2 deletion with CREBBP and KRAS mutations in pediatric high-hyperdiploid acute lymphoblastic leukemia.
    Ueyama JI; Miki M; Okuno K; Eto S; Shimada A
    Pediatr Int; 2017 Oct; 59(10):1103-1105. PubMed ID: 28856790
    [No Abstract]   [Full Text] [Related]  

  • 5. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
    Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Husemann P; Krell PF; Borkhardt A; Dugas M; Hu J; Fischer U
    Leuk Res; 2015 Sep; 39(9):990-1001. PubMed ID: 26189108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
    Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
    Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia.
    Gao C; Zhang RD; Liu SG; Zhao XX; Cui L; Yue ZX; Li WJ; Chen ZP; Li ZG; Rao Q; Wang M; Zheng HY; Wang JX
    Eur J Haematol; 2017 Aug; 99(2):150-159. PubMed ID: 28452416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma.
    Martin-Guerrero I; Salaverria I; Burkhardt B; Chassagne-Clement C; Szczepanowski M; Bens S; Klapper W; Zimmermann M; Kabickova E; Bertrand Y; Reiter A; Siebert R; Oschlies I
    Genes Chromosomes Cancer; 2019 Jun; 58(6):365-372. PubMed ID: 30578714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay.
    Chen C; Heng EYH; Lim AST; Lau LC; Lim TH; Wong GC; Tien SL
    Int J Lab Hematol; 2019 Aug; 41(4):561-571. PubMed ID: 31112375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive profiling of disease-relevant copy number aberrations for advanced clinical diagnostics of pediatric acute lymphoblastic leukemia.
    Kiss R; Gángó A; Benard-Slagter A; Egyed B; Haltrich I; Hegyi L; de Groot K; Király PA; Krizsán S; Kajtár B; Pikó H; Pajor L; Vojcek Á; Matolcsy A; Kovács G; Szuhai K; Savola S; Bödör C; Alpár D
    Mod Pathol; 2020 May; 33(5):812-824. PubMed ID: 31857684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
    Reismüller B; Steiner M; Pichler H; Dworzak M; Urban C; Meister B; Schmitt K; Pötschger U; König M; Mann G; Haas OA; Attarbaschi A;
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27804199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials.
    Enshaei A; Vora A; Harrison CJ; Moppett J; Moorman AV
    Lancet Haematol; 2021 Nov; 8(11):e828-e839. PubMed ID: 34715050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia.
    Kawamura M; Kikuchi A; Kobayashi S; Hanada R; Yamamoto K; Horibe K; Shikano T; Ueda K; Hayashi K; Sekiya T
    Blood; 1995 May; 85(9):2546-52. PubMed ID: 7727782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia.
    Blau O; Avigad S; Stark B; Kodman Y; Luria D; Cohen IJ; Zaizov R
    Leuk Res; 1997 Aug; 21(8):721-9. PubMed ID: 9379679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis.
    Irving JA; Bloodworth L; Bown NP; Case MC; Hogarth LA; Hall AG
    Cancer Res; 2005 Apr; 65(8):3053-8. PubMed ID: 15833833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.
    Xiao H; Wang LM; Luo Y; Lai X; Li C; Shi J; Tan Y; Fu S; Wang Y; Zhu N; He J; Zheng W; Yu X; Cai Z; Huang H
    Oncotarget; 2016 Jan; 7(3):2696-708. PubMed ID: 26527318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
    Mar BG; Bullinger LB; McLean KM; Grauman PV; Harris MH; Stevenson K; Neuberg DS; Sinha AU; Sallan SE; Silverman LB; Kung AL; Lo Nigro L; Ebert BL; Armstrong SA
    Nat Commun; 2014 Mar; 5():3469. PubMed ID: 24662245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course.
    Irving JA; Minto L; Bailey S; Hall AG
    Cancer Res; 2005 Nov; 65(21):9712-8. PubMed ID: 16266991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index < 1.16.
    Zaliova M; Hovorkova L; Vaskova M; Hrusak O; Stary J; Zuna J
    Genes Chromosomes Cancer; 2016 Sep; 55(9):727-37. PubMed ID: 27163296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.
    Sadras T; Heatley SL; Kok CH; McClure BJ; Yeung D; Hughes TP; Sutton R; Ziegler DS; White DL
    Cancer Genet; 2017 Oct; 216-217():86-90. PubMed ID: 29025600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.